Baseline modern medical management in the BEST-CLI trial

Matthew T Menard1, Michael R Jaff2, Alik Farber3

  • 1Division of Vascular and Endovascular Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Insights

Optimal medical therapy (OMT) adherence is low in patients with chronic limb-threatening ischemia (CLTI). Only 25% of patients met all four OMT criteria at trial entry, highlighting a gap in care for advanced peripheral atherosclerosis.

Area of Science:

  • Vascular Surgery
  • Cardiology
  • Internal Medicine
  • Clinical Trials

Background:

  • Optimal medical therapy (OMT) is crucial for managing patients with chronic limb-threatening ischemia (CLTI).
  • The adherence to guideline-based OMT in CLTI patients has not been extensively studied.
  • The Best Endovascular vs Best Surgical Therapy in Patients with CLTI (BEST-CLI) trial provides a unique opportunity to evaluate OMT use.

Purpose of the Study:

  • To assess the utilization of guideline-based optimal medical therapy (OMT) in patients with chronic limb-threatening ischemia (CLTI) at the time of enrollment in the BEST-CLI trial.
  • To identify factors associated with OMT adherence in this patient population.

Main Methods:

  • A multidisciplinary committee defined OMT criteria including blood pressure, diabetes management, lipid-lowering, antiplatelet use, and smoking status.
  • Data on baseline demographics, comorbidities, and OMT adherence were collected for 1830 randomized patients in the BEST-CLI trial.
  • A linear regression model was employed to determine predictors of OMT use.

Main Results:

  • At randomization, a high prevalence of comorbidities was observed: 87% hypertension, 69% diabetes, 73% hyperlipidemia, and 35% current smokers.
  • Adherence to OMT was modest, with only 25% of patients meeting all four defined criteria (controlled blood pressure, non-smoking, lipid-lowering medication, antiplatelet agent).
  • Older age (≥80 years), coronary artery disease, diabetes, and Hispanic ethnicity were positively associated with OMT use, while Black race showed a negative association.

Conclusions:

  • A significant proportion of patients with CLTI in the BEST-CLI trial did not meet guideline-based OMT recommendations upon enrollment.
  • These findings indicate a substantial gap in the medical management of patients with advanced peripheral atherosclerosis and CLTI.
  • Future analyses will examine changes in OMT adherence and its impact on clinical outcomes and quality of life throughout the trial.
Abstract

Related Concept Videos

Methods of Documentation VI: Case Management Model01:15

Methods of Documentation VI: Case Management Model

The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
For example, a patient with a chronic...
604
Blinding01:11

Blinding

Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
2.5K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.1K
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
14
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
16
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
22